Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. - Wikidata - awgldk - TriplyDB

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

http://www.wikidata.org/entity/Q37685652

about

Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer Active surveillance for prostate cancer: when to recommend delayed intervention Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countries Active surveillance monitoring: the role of novel biomarkers and imaging Active surveillance for prostate cancer: current evidence and contemporary state of practice Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS)Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.The prostate health index selectively identifies clinically significant prostate cancer.Risk stratification of prostate cancer in the modern era.Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort The Prostate Health Index: Its Utility in Prostate Cancer Detection Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Sarcosine as a potential prostate cancer biomarker--a review Biomarkers for prostate cancer: present challenges and future opportunities.The Prostate Health Index: a new test for the detection of prostate cancer.Implementation of PSA-based active surveillance in prostate cancer.Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.Baseline and Longitudinal Plasma Caveolin-1 Level as a Biomarker in Active Surveillance for Early Stage Prostate Cancer.Expectant management for men with early stage prostate cancer.Biomarkers in localized prostate cancer.Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.Current Management Strategy for Active Surveillance in Prostate Cancer.The role of prostate cancer biomarkers in undiagnosed men.The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA i Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging.Active Surveillance of Prostate Cancer.The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance.Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort.Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.Prostate cancer: Predicting prostate biopsy results--PCA3 versus phi.Shift from protocol-based to personalized medicine in active surveillance: beginning of a new era.Serum marker %[-2]proPSA and the Prostate Health Index improve diagnostic accuracy for clinically relevant prostate cancer.

P2860

Q26784517-0AAB44CE-8238-47A0-A7C7-75E602043A8D Q26801195-9AD94886-4525-4E18-8F84-A34B74FD8E00 Q26824913-24104396-942F-41C1-BD90-54898E1A8FDF Q26996461-32A99835-0601-458A-B784-24ED759F749B Q27007131-073A46DB-F6C7-489B-AA88-61C18FA942C1 Q28066534-3988ACE9-355D-4309-93B2-3C9F652D1760 Q33838513-F07E71A3-E6A1-4B89-A715-15C2BEC19905 Q33911725-42462EFC-605D-427F-AE49-0923D1F172EE Q34825819-A6782B52-B169-492A-9E74-4A768EF19481 Q35471903-5438CF62-1378-4C7D-8755-019243B49A93 Q35498981-27C72CA8-41CF-4C46-BDE2-4C766AC124D1 Q35680101-A8FF9A4F-3D7B-4851-A377-CDC90EF92964 Q36238237-B4B1D62B-784A-4EEF-B452-5543C661C524 Q36328005-E64FC3DC-09CA-4FC6-84C9-DC9F7D5E5775 Q37029385-BDB6F6E2-0AD3-439B-B8D8-E65B1265BDAF Q37091881-E28FB9ED-9CC4-4A2A-BC7E-A7F1A92E77DF Q37474443-E70FAED1-4DAC-466A-9515-7F2844B96270 Q37619016-C6700E9F-6C99-4227-8160-BB697296D7B3 Q38239830-EB722F20-631F-49B3-B049-5321AF1776CD Q38241107-B08BF5F5-13BB-4636-91F6-82A6D588C727 Q38373132-04966000-1CA8-4917-B6FE-026A2FE08AFD Q38469754-B1851387-F808-4610-AFAE-BD41BC6ABFDD Q38697114-3D7BF4E5-9E9E-4385-8352-BEEDC37B6783 Q38812336-06AE4F07-7FB8-4515-B749-3385EF474ABC Q38854599-FB9A6596-FCD2-4BF1-8AE1-7F54C753A8E1 Q38891544-664BA09A-8581-4DA2-B3CB-D9DF10B1113A Q38950908-72D76FE9-D492-47FE-BE6D-8E804F68079B Q39140686-3E6E87B4-3414-4DA7-8C63-25D3783182D3 Q40267154-E70949C9-7241-4A29-8A9B-BE172E7DD041 Q40412845-A6006F43-0CF7-4044-B72D-D8ADDC738573 Q40458086-FC32106C-386C-4DC1-91F0-82C6A50B8F74 Q41377631-803A03B8-51F4-4D05-A046-E363B243C492 Q41878045-00AC72F7-371F-4EC3-A8F9-D71D9103D6A4 Q47149516-66564047-D524-4BAD-9702-AAF7E5E88867 Q47355040-51D5A157-7DAA-4984-A060-EB530201C62B Q47436741-D4B7D76D-F7A1-43C5-914F-F986B63E26A5 Q47718669-21268253-7B23-4289-844B-D829521B114A Q48123707-E77A9735-C795-4DD8-B201-6CA5EA207062 Q53216904-C53F7464-C4AD-4066-90E2-953186987815 Q53241336-6A4D6FBC-95DA-4592-9834-36E90FA18C7D

P2860

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

http://www.wikidata.org/entity/Q37685652

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 August 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Association of [-2]proPSA with ...... veillance for prostate cancer.

@en

Association of [-2]proPSA with ...... veillance for prostate cancer.

@nl

type

label

Association of [-2]proPSA with ...... veillance for prostate cancer.

@en

Association of [-2]proPSA with ...... veillance for prostate cancer.

@nl

prefLabel

Association of [-2]proPSA with ...... veillance for prostate cancer.

@en

Association of [-2]proPSA with ...... veillance for prostate cancer.

@nl

P1433

Q37685652-683BFA87-4C43-4F64-8CB7-07022EB443D5

P1476

Q37685652-E9797186-65EB-421D-98FB-6EB2A88FCBC9

P2093

Q37685652-140E8765-5FA2-4AD8-A186-B406CACB24FE

Q37685652-1471230B-BB65-439A-84AB-FDCB375E6CD2

Q37685652-1A1372BA-2F93-40BE-B0B8-7C1E0DB9FD9E

Q37685652-1BBE90A3-B875-4757-955F-469473BB72B4

Q37685652-3FCECB3C-F839-4054-906E-6D311E428207

Q37685652-7D1AA670-CD91-4B61-BA25-9DB0B7F2A97A

Q37685652-A635F5D2-F5C1-4D11-A9B8-4D652884AE9F

Q37685652-BA15837C-0353-40BB-8409-788B8EBECA98

Q37685652-D00CC55E-F9EB-49A4-82D2-809535D92572

P2860

Q37685652-055F0B72-72F1-437C-9518-C64751D852AF

Q37685652-06EB61EF-5038-4753-8D97-3398C104AB34

Q37685652-0C571D63-666C-43E6-8A23-6C9740388C25

Q37685652-145F99A0-6FE3-41D2-9E0C-7CC7A0EA5307

Q37685652-1769D31F-76E9-4231-BC37-912F7B0A7791

Q37685652-3444B04E-677F-4A87-B7E5-5AF350964A4D

Q37685652-445EA54D-516E-4C66-BE27-0077AAA3657D

Q37685652-4D78E308-02E2-4F69-9ED2-49B9262525A3

Q37685652-6879FFD8-4B18-4867-AE91-77191B2AE0B4

Q37685652-6A41B528-DC38-4B8E-925F-6AF7DE235191

P304

Q37685652-8DBB456B-6593-42BE-83B9-059519AE829C

P31

Q37685652-5886D7AD-A3A8-413D-AD1B-8F26275CD4D1

P356

Q37685652-0830F7BF-A83D-401C-B0DE-309E9B7AEBA4

P407

Q37685652-4933053C-2AFF-4E5C-8FC9-0D18F8D1D7B2

P433

Q37685652-A825FE06-4D30-45AF-9A10-1A0CF01FA6A8

P478

Q37685652-97D678A9-2395-4C86-B60D-186EB08F8D8C

P50

Q37685652-5F90D616-7004-4EAC-BD8F-EE40E9C90490

Q37685652-5F9EFCE1-E8B6-4BA4-BCAE-4B06586F959A

Q37685652-7901498D-9956-4FB6-B883-D51E9BFE97DD

P577

Q37685652-98833514-744A-4F91-9E80-319E7C1B2085

P5875

Q37685652-D2FFBC92-87DC-438E-A91F-651EFD3F3D41

P698

Q37685652-F50BB54C-63C8-4C78-A5FC-35A10BE692E8

P921

Q37685652-555B8D53-957D-42F8-9542-D4B4AD35C818

P932

Q37685652-37534E21-ED18-4524-A75F-E7C71F00E1AB

P356

J.JURO.2012.06.009

P1433

The Journal of Urology

P1476

Association of [-2]proPSA with ...... veillance for prostate cancer.

@en

P2093

Bruce Trock

http://www.w3.org/2001/XMLSchema#string

Debra J Elliot

http://www.w3.org/2001/XMLSchema#string

H Ballentine Carter

http://www.w3.org/2001/XMLSchema#string

Jonathan I Epstein

http://www.w3.org/2001/XMLSchema#string

Lori J Sokoll

http://www.w3.org/2001/XMLSchema#string

Patricia Landis

http://www.w3.org/2001/XMLSchema#string

Robert Veltri

http://www.w3.org/2001/XMLSchema#string

Sumit Isharwal

http://www.w3.org/2001/XMLSchema#string

Zhaoyong Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Attrition in longitudinal studies. How to deal with missing data.

Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry.

Time-dependent covariates in the Cox proportional-hazards regression model.

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.

NCCN clinical practice guidelines in oncology: prostate cancer.

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.

Risk stratification of men choosing surveillance for low risk prostate cancer.

Delayed versus immediate surgical intervention and prostate cancer outcome

P304

1131-1136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2012.06.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

188

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey J Tosoian

P577

2012-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230696729

http://www.w3.org/2001/XMLSchema#string

P698

22901577

http://www.w3.org/2001/XMLSchema#string

P921

P932

3976250

http://www.w3.org/2001/XMLSchema#string